TCI Wealth Advisors’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-106
Closed -$4.39K 369
2023
Q1
$4.39K Buy
106
+105
+10,500% +$4.36K ﹤0.01% 1617
2022
Q4
$44 Sell
1
-98
-99% -$4.09K ﹤0.01% 2437
2022
Q3
$4K Buy
99
+1
+1% +$46 ﹤0.01% 1567
2022
Q2
$4K Buy
+98
New +$4.64K ﹤0.01% 1587
2022
Q1
Sell
-89
Closed -$6K 2222
2021
Q4
$6K Buy
89
+2
+2% +$145 ﹤0.01% 1497
2021
Q3
$6K Hold
87
﹤0.01% 1419
2021
Q2
$7K Buy
87
+55
+172% +$4K ﹤0.01% 1180
2021
Q1
$2K Buy
+32
New +$1.97K ﹤0.01% 1666

Other funds holding ATRC

TCI Wealth Advisors's ATRC Position: Q2 2023 in Review

TCI Wealth Advisors sold out of AtriCure (ATRC) in Q2 2023, closing a stake of 106 shares — an estimated $4.39K sold.

TCI Wealth Advisors first reported a position in ATRC in Q1 2021 and held it in 8 quarters. The position peaked at $7K in Q2 2021. 223 funds tracked by Wall St. Rank hold ATRC as of Q2 2023.

  • TCI Wealth Advisors reported no remaining AtriCure position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 106 AtriCure shares in Q2 2023, an estimated $4.39K.
  • TCI Wealth Advisors first reported a position in AtriCure in Q1 2021 and held it in 8 quarters.
  • TCI Wealth Advisors's AtriCure position peaked at $7K in Q2 2021.
  • 223 funds tracked by Wall St. Rank held AtriCure as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.